Clinical Trial Update: Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. [Phase 2]

View source ↗

Summary

Phase II trial of NGR-hTNF in combination with doxorubicin for metastatic soft tissue sarcoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• Doxorubicin (doxorubicin)
• NGR-hTNF (NGR-hTNF)

Snippet

Sponsor: AGC Biologics S.p.A. | Conditions: Metastatic Adult Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED